舒林酸对卵巢癌细胞系CP70顺铂耐药性的逆转作用  

Sulindac resensitizes cisplatin-resistant human ovarian cancer cells CP70

作　　者：邵娟[1] 辛晓燕[1] 魏燕[1] 段海霞[1] 

机构地区：[1]第四军医大学西京医院妇产科,陕西西安710032

出　　处：《现代肿瘤医学》2011年第2期208-211,共4页Journal of Modern Oncology

摘　　要：目的:研究舒林酸体外逆转卵巢癌细胞系CP70的顺铂耐药性,并探讨其与β-catenin表达的关系。方法:MTT法检测单独使用舒林酸或顺铂及两药联合使用时对CP70细胞的抑制作用,免疫细胞化学和Western blot方法检测细胞内β-catenin表达水平。结果:两药联合处理细胞后顺铂耐药逆转倍数为6.01,联合处理组的细胞中β-catenin表达明显降低。结论:舒林酸能部分逆转CP70细胞对顺铂的耐药性,且此作用可能与下调细胞的β-catenin表达有关。Objective：To study the effect of sulindac in resensitizing cisplatin - resistant human ovarian cancer cells CP70, and to discuss the related mechanism. Methods： MTF assay was used to assess the inhibitory effects of sulindae, cisplatin alone or a combination of both on CP70 cells. Immunohistochemical analysis and Western blotting were employed to observe the expression of β - catenin in different groups. Results： The resensitizing fold of cisplatin combined with sulindac was 6.01. The expression of β - catenin had the most prominent decrease in CP70 cells in the combination group. Conclusion： Sulindac can partially resensitize cisplatin -resistant CP70 cells,which might be related to the down - regulation of β- catenin.

关 键 词：舒林酸 卵巢癌 顺铂 耐药性 

分 类 号：R73-361[医药卫生—肿瘤] R737.31[医药卫生—临床医学]